Haemostatic effectiveness of intranasal desmopressin for tunnelled dialysis catheter placement: a pilot randomised controlled trial

What Was Tested

Researchers studied Vasopressin and Desmopressin in this randomized controlled trial publication.

Iranian Clinical Trial Registry (IRCT20240215061017N2).

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

This open-label randomised controlled trial was done on patients aged ≥ 12 years undergoing placement of tunnelled dialysis catheters.

Exclusion criteria included current use of anticoagulants, platelet count < 50 × 109/l, previous tunnelled dialysis catheter insertions at the same site, blood pressure > 180/110 mmHg, and unwillingness.

How the Study Was Run

The design is described as randomized, open-label and pilot.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Vasopressin study did not mask who received what.

It is described as a pilot, a small early test of whether a larger Vasopressin study would be practical.

Patients in the control arm did not receive desmopressin.

All patients were monitored for bleeding from the TDC exit site for 24 h after the procedure.

For persistent bleeding, a purse-string suture was applied approximately 1 cm from the exit site.

What Was Measured

Topics PubMed links to this paper include Pilot Projects, Hemostatics, Deamino Arginine Vasopressin, Renal Dialysis, Catheters, Indwelling, Hemorrhage and Catheterization, Central Venous.

The authors tagged it with the keywords Central venous catheters, Hemostasis, Intranasal administration, Uremia and Vascular access devices.

What This Means in Plain Language

The paper is a randomized, open-label and pilot study of Vasopressin and Desmopressin.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (International urology and nephrology), a journal based in Netherlands.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.